6 recruiting, 4 completed, 4 withdrawn, 2 active not recruiting. 17 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Recruiting 6, Completed 4, Withdrawn 4, Active not recruiting 2, Terminated 1 |
| Phase 1 | 3 | Withdrawn 2, Completed 1 |
Follow Pancreas Adenocarcinoma: new trials by email Literature Review of Pancreas Adenocarcinoma trials Research Report on Pancreas Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Yale University | 54 | 2026-06-02 | 2026-09-08 |
| 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX) - Pancreas Adenocarcinoma | Phase 2 | Recruiting | Dartmouth-Hitchcock Medical Center | 35 | 2025-09-29 | 2026-08-06 |
| CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) Capecitabine - Pancreas Cancer, Pancreas Adenocarcinoma | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2024-12-01 | 2024-08-15 | |
| NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101 Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101 - Pancreas Adenocarcinoma | Phase 2 | Recruiting | Leiden University Medical Center | 20 | 2024-03-18 | 2024-04-04 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1 / Phase 2 | Completed | Immuneering Corporation | 30 | 2024-02-27 | 2025-05-28 |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, Radiological Assessments - Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Wake Forest University Health Sciences | 64 | 2023-08-01 | 2026-09-28 |
| Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) Enfortumab vedotin - Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 28 | 2023-06-30 | 2025-04-16 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 CRGD-ZW800-1, Intraoperative near-infrared fluorescence imaging - Pancreas Adenocarcinoma, Cholangiocarcinoma | Phase 2 | Completed | Leiden University Medical Center | 20 | 2022-11-09 | 2024-06-24 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy - Pancreas Cancer, Cancer of the Pancreas | Phase 2 | Active not recruiting | Washington University School of Medicine | 42 | 2021-08-24 | 2026-05-08 |
| The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. Gemcitabine - Pancreas Adenocarcinoma | Phase 2 | Withdrawn | Yale University | 2019-11-15 | 2020-01-09 | |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Gemcitabine 1000 mg, nab-paclitaxel, Stereotactic Body Radiation Therapy - Pancreas Adenocarcinoma, Resectable Pancreatic Cancer | Phase 2 | Recruiting | Loma Linda University | 30 | 2019-07-17 | 2025-10-02 |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Oxaliplatin, Leucovorin, Irinotecan Hydrochloride - Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2019-06-12 | 2026-01-13 |
| Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy Hemopatch - Pancreas Cancer, Pancreas Disease | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 52 | 2018-08-13 | 2021-11-03 |
| Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative chemotherapy, Preoperative radiotherapy - Cancer of Pancreas, Pancreas Adenocarcinoma | Phase 2 | Terminated | CNAO National Center of Oncological Hadrontherapy | 30 | 2018-02-08 | 2025-02-13 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Pembrolizumab, paricalcitol, placebo - Pancreatic Cancer, Pancreas Adenocarcinoma | Phase 2 | Completed | Translational Genomics Research Institute | 24 | 2017-12-27 | 2022-12-27 |
Pancreatic Neoplasms (10) · Cholangiocarcinoma (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Melanoma, Cutaneous Malignant (1) · Mesothelioma (1) · Pancreatic Diseases (1) · Pancreatic Fistula (1) · Pancreatic cancer, adult (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Neoplasms (14) · Neoplasms by Site (12) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Pancreatic Diseases (9) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (3) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2)
Gemcitabine (5) · 130-nm albumin-bound paclitaxel (4) · Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Oxaliplatin (2) · pembrolizumab (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Heavy Ion Radiotherapy (1) · Radiosurgery (1) · Taxes (1) · atezolizumab (1) · defactinib (1) · enfortumab vedotin (1)
Leiden University Medical Center (2) · Yale University (2) · CNAO National Center of Oncological Hadrontherapy (1) · Case Comprehensive Cancer Center (1) · Dartmouth-Hitchcock Medical Center (1) · Immuneering Corporation (1) · Lisata Therapeutics, Inc. (1) · Loma Linda University (1) · Rain Oncology Inc (1) · Sunnybrook Health Sciences Centre (1) · Translational Genomics Research Institute (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Kansas Medical Center (1) · Wake Forest University Health Sciences (1) · Washington University School of Medicine (1)
United States (10) · Netherlands (2) · Canada (1) · Italy (1)
Ashwin Somasundaram, MD (1) · Carl DeSelm, M.D., Ph.D. (1) · Daniel D Von Hoff, MD, FACS (1) · Francesca Valvo, MD (1) · Kiran Turaga, MD (1) · Kristen K. Buck, MD (1) · Lee M Ocuin, MD, FACS (1) · Michael Cecchin, MD (1) · Naveenraj Solomon, MD (1) · Paul Karanicolas, MD (1) · Ravi K Paluri, MD, MPH (1) · Vinny Hayreh, MD (1)
PMID 31521134, PMID 34176743, PMID 37598000, PMID 39462835, PMID 39846984
2019 (1), 2023 (1), P30CA012197 (1), R01CA248917 (1)